14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CTSO ranks #14331 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Cytosorbents Corporation Stock Forecast NASDAQ:CTSO

$3.42 (0.88%)

Volume: 323k

Closed: Jan 19, 2022

Hollow Logo Score: -3.307

Cytosorbents Corporation Stock Forecast

$3.42 (0.88%)

Volume: 323k

Closed: Jan 19, 2022

Score Hollow Logo -3.307

Cytosorbents Corporation Company Profile

7 Deer Park Drive

Monmouth Junction NJ 08852



Industry: Medical Devices

Sector: Healthcare

Cytosorbents Corporation


CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications; the prevention of post-operative complications of cardiopulmonary bypass surgery and damage to organs donated by brain-dead donors prior to organ harvest; the treatment of cancer cachexia; the prevention of transfusion reactions caused by contaminants in transfused blood products; and the prevention of contrast induced nephropathy, the treatment of drug overdose, and the treatment of chronic kidney failure. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE